A phase II randomized continuation booster trial after a vaccine combining tyrosinase/GP100/Mart-1 peptides emulsified with montanide ISA-51 and ISA-51 VG with or without GM-CSF [granulocyte macrophage colong-stimulating factor; sargramostim] for patients with resected stage IIB/C, III and IV melanoma.
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Melanoma vaccine (Primary) ; Montanide ISA-51; Sargramostim
- Indications Malignant melanoma
- Focus Therapeutic Use
- 15 Apr 2015 Biomarkers information updated
- 31 Oct 2005 New trial record.